Aripiprazole: In acute mania associated with bipolar I disorder

CNS Drugs

Volumn 18, Issue 6, 2004, Pages 367-376

  Lyseng Williamson, Katherine A ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; FAMOTIDINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PLACEBO; QUINOLONE DERIVATIVE; SEROTONIN 1A RECEPTOR; VALPROATE SEMISODIUM; VALPROIC ACID;

AGITATION; AGONIST; AKATHISIA; BIPOLAR I DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; MANIA; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RATING SCALE; RECURRENCE RISK; RELAPSE; REVIEW; SOMNOLENCE; SYMPTOM; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION; DRUG TOLERANCE; HUMANS; PIPERAZINES; PRACTICE GUIDELINES; QUINOLONES;

EID: 2442624599     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418060-00007     Document Type: Review

References (37)

1. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 Apr; Spec No: 1-104
2. Kleinman LS, Lowin A, Flood E, et al. Costs of bipolar disorder. Pharmacoeconomics 2003; 21 (9): 601-22
3. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003 Apr; 64 (4): 425-32
4. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 Apr; 159 (4 Suppl.): 1-50
5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
6. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996 Jul 23-31; 276 (4): 293-9
7. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Consensus Group of the British Association for Pshycopharmacology. J Psychopharmacol 2003 Jun; 17 (2): 149-73
8. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part II: treatment of mania. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. World J Biol Psychiatry 2003 Jan; 4 (1): 5-13
9. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 2001 Dec; 62 (12): 923-4
10. Keltner NL, Johnson V. Biological perspectives. Aripiprazole: a third generation of antipsychotics begins? Perspect Psychiatr Care 2002 Oct-Dec; 38 (4): 157-9
11. Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem 1998 Feb 26; 41 (5): 658-67
12. Sasa M, Amano T. Unique pharmacological profile of a novel antipsychotic drug, aripiprazole (OPC-14597). CNS Drug Rev 1997; 3 (1): 24-33
13. Keck Jr PE, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003 Apr; 12 (4): 655-62
14. Ozdemir V, Fourie J, Ozdener F. Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Investig Drugs 2002 Jan; 3(1): 113-20
15. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16 (11): 779-86; discussion 787-8
16. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004 Feb; 44 (2): 179-98
17. Bristol-Myers Squibb Company. Abilify (aripiprazole) tablets: US prescribing information [online]. Available from URL: http://www.bms.com [Accessed 2003 Nov 3]
18. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 Jul; 302 (1): 381-9
19. 11C]raclopride. Neuropsychopharmacology 2002 Aug; 27 (2): 248-59
20. 2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997 Feb 19; 321 (1): 105-11
21. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999 Jun; 20 (6): 612-27
22. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003 Aug; 28 (8): 1400-11
23. 1A receptor. Eur J Pharmacol 2002 Apr 26; 441 (3): 137-40
24. Mallikaarjun S, Riesgo Y, Salazar D, et al. Time of dosing and food effect on aripiprazole pharmacokinetics [abstract no. P.2.120]. Eur Neuropsychopharmacol 2003 Sep; 13 Suppl. 4: S332-3
25. Citrome L, Josiassen R, Bark N, et al. Pharmacokinetics and safety of aripiprazole and concomitant mood stabilizers [abstract no. P.4.E.035]. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S187
26. Bramer S, Shoaf S, Salazar D, et al. Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole [abstract no. P.2.122]. Eur Neuropsychopharmacol 2003 Sep; 13 Suppl. 4: S333
27. Mallikaarjun S, Tammara BK, Salazar DE, et al. The effects of hepatic impairment on the pharmacokinetics of aripiprazole [abstract no. TPII-91]. Clin Pharmacol Ther 2002 Feb; 71 (2): 66
28. Mallikaarjun S, Ali MW, Salazar DE, et al. The effects of age and gender on the pharmacokinetics of aripiprazole [abstract no. TPII-90]. Clin Pharmacol Ther 2002 Feb; 71 (2): 66
29. Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Aripiprazole Study Group. Am J Psychiatry 2003 Sep; 160 (9): 1651-8
30. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole versus placebo in acute mania: results from a second study [poster]. American Psychiatric Association, Institutes on Psychiatric Services; 2003 Oct 29-Nov 2; Boston
31. Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co. Ltd. Supplemental new drug application submitted for ABILIFY(TM) (aripiprazole) for the treatment of acute bipolar mania [media release]. 2003 Jul 16
32. Bourin M, Auby P, Marcus RN, et al. Aripiprazole versus haloperidol for maintained treatment effect in acute mania [abstract no. NR467 plus poster]. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, 175
33. Marcus R, Carson WH, McQuade RD, et al. Long-term efficacy of aripiprazole in the maintenance treatment of bipolar disorder [abstract no. 111]. American College of Neuropsychopharmacology 42nd Annual Meeting; 2003 Dec 7-11; San Juan, Puerto Rico
34. McQuade R, Marcus R, Sanchez R, et al. Aripiprazole vs. placebo in acute mania: safety and tolerability pooled analysis [poster]. 5th International Conference on Bipolar Disorder; 2003 June 12-14; Pittsburgh
35. Bristol-Myers Squibb Company, Otsuka Pharmaceuticals Co. Ltd. Results from new clinical studies: aripiprazole significantly improved symptoms of acute bipolar mania [media release]. 2003 May 20
36. Berardi D, Giannelli A, Barnes TRE. Clinical correlates of akathisia in acute psychiatric inpatients. Int Clin Psychopharmacol 2000; 15 (4): 215-9
37. Data on file. Bristol-Myers Squibb Company, 2004 Mar 13